ArticleScientific reports2025
Preoperative prediction of the HER2 status and prognosis of patients with endometrial cancer using multiparametric MRI-based radiomics: a multicenter study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Internal Validation of a Nomogram for Predicting Recurrence in Endometrial Cancer Based on Pathological and Histological Indicators.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Non-invasive preoperative assessment of HER2 status is critical for identifying candidates for targeted therapy and personalizing treatment strategies in endometrial cancer (EC). This study aims to assess the preoperative value of multiparametric magnetic resonance imaging (MRI)-based radiomics in predicting HER2 status and prognosis of EC patients. We included 492 patients with EC divided into training (n = 215), internal validation (n = 92), and external validation cohorts 1 (n = 64) and 2 (n = 121). Models were constructed using six machine learning algorithms based on radiomics features derived from multiparametric MRI, including T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted sequences. A fusion model integrating key clinical predictors with the radiomics score (Rad-score) was created. Its predictive performance was evaluated through receiver operating characteristic (ROC) analysis, and its prognostic significance was assessed through survival analysis. HER2 (+) status was associated with poor differentiation and myometrial invasion in patients with EC. A support vector machine (SVM)-based model comprised of multiparametric MRI-based radiomics features demonstrated excellent performance in predicting HER2 status, with a mean area under the ROC curve (AUC) of 0.814 in the validation cohorts. A fusion model combining the SVM-based Rad-score with clinical factors significantly improved prediction accuracy, achieving AUCs of 0.914 in the training cohort, and 0.809-0.865 in the validation cohorts. Kaplan-Meier analysis revealed that patients with EC with predicted HER2 (+) status had worse progression-free survival than those with predicted HER2 (-) status. The fusion model based on multiparametric MRI-based radiomics features can potentially aid in the accurate preoperative prediction of HER2 status and prognosis of patients with EC, providing essential insights for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.